The U.S. Food and Drug Administration (FDA) granted orphan-drug designation (ODD) to TTX101 for use in patients with malignant gliomas.
Headquarters
Avenida Tenente Valadim, No 17, 2º F 2560-275 Torres Vedras - Portugal
Office
Complexo Interdisciplinar de Lisboa, Avenida Professor Gama Pinto, No 2, Office B2.05, 1649-003 Lisbon - Portugal
Avenida Tenente Valadim, No 17, 2º F 2560-275 Torres Vedras - Portugal
Office
Complexo Interdisciplinar de Lisboa, Avenida Professor Gama Pinto, No 2, Office B2.05, 1649-003 Lisbon - Portugal
